ストックスクリーナーアプリを入手
15.65
0.45%
0.07
前日終値:
$15.58
開ける：
$15.59
24時間の取引高:
1.23M
Relative Volume:
0.44
時価総額：
$49.44B
収益：
$29.63B
当期純損益:
$260.53M
株価収益率:
198.60
EPS:
0.0788
ネットキャッシュフロー:
$5.51B
1週間 パフォーマンス:
+5.03%
1か月 パフォーマンス:
+7.78%
6か月 パフォーマンス:
+3.92%
1年 パフォーマンス:
+19.10%
1日の値動き範囲:
$15.55
$15.66
1週間の範囲:
$14.85
$15.66
52週間の値動き範囲:
$12.80
$15.69
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
TAK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.65 | 49.22B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
ZTS
Zoetis Inc
|
126.23 | 55.30B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.89 | 36.41B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
507.16 | 22.16B | 3.08B | 1.24B | 1.07B | 25.61 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛
Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria
CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com
BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com
CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se
INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com
INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo
Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com
5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool
Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
0.30%
1.45%
大文字化:
|
ボリューム (24 時間):